Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 272 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Plavix Clear all
Completed No phase listed Observational

Replication of the TRITON-TIMI Antiplatelet Trial in Healthcare Claims Data

NCT04237922
View directory record Official record
Conditions
Antiplatelet
Interventions
Prasugrel 10mg, Clopidogrel 75mg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
43,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 29, 2026, 1:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

NCT01094275
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel 75mg, Omeprazole 20mg
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 29, 2026, 1:23 PM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 3 Interventional

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

NCT00050817
View directory record Official record
Conditions
Arteriosclerosis
Interventions
clopidogrel (SR25990)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older
Enrollment
15,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

NCT04484259
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Clopidogrel and Rosuvastatin

NCT01469416
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Clopidogrel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 29, 2026, 1:23 PM EDT
Terminated Phase 3 Interventional Results available

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

NCT00991029
View directory record Official record
Conditions
Ischemic Attack, Transient
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
147
States / cities
Chandler, Arizona • Tucson, Arizona • Carmichael, California + 95 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 29, 2026, 1:23 PM EDT
Terminated Not applicable Interventional

Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)

NCT01177592
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
VerifyNow, Verigene
Device
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

NCT00357968
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 2Phase 3 Interventional

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

NCT00109382
View directory record Official record
Conditions
Transient Ischemic Attack, Stroke
Interventions
Aspirin, Clopidogrel, Simvastatin
Drug
Lead sponsor
University of Calgary
Other
Eligibility
40 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2008 · Synced Oct 29, 2026, 1:23 PM EDT
Completed No phase listed Observational

Pharmacogenomics and Effective Treatment With Clopidogrel

NCT01611545
View directory record Official record
Conditions
Pharmacogenomics and Cardiovascular Events
Interventions
Pharmacogenomics
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Davenport, Iowa • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor

NCT00102674
View directory record Official record
Conditions
Healthy
Interventions
cangrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

NCT00621855
View directory record Official record
Conditions
Coronary Disease
Interventions
placebo, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

NCT00059215
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases
Interventions
Prasugrel (CS-747), Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2010 · Synced Oct 29, 2026, 1:23 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

NCT03787927
View directory record Official record
Conditions
Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
Interventions
Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (cold-stored 15 days), Aspirin, Clopidogrel
Drug
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 29, 2026, 1:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance Evaluation of T-TAS 01 PL Chip

NCT03621020
View directory record Official record
Conditions
Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
Interventions
T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
21 Years and older
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Low Risk Acute Coronary Syndrome

NCT01703156
View directory record Official record
Conditions
Low Risk Acute Coronary Syndrome
Interventions
Stress Test, No Stress Test
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

NCT02833948
View directory record Official record
Conditions
Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Interventions
Acetylsalicylic acid, Clopidogrel, Rivaroxaban
Drug
Lead sponsor
ECRI bv
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Not applicable Interventional Results available

The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

NCT00644657
View directory record Official record
Conditions
Coronary Artery Disease, Chest Pain
Interventions
Clopidogrel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 29, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

NCT01511939
View directory record Official record
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 29, 2026, 1:23 PM EDT